MGX Metagenomi Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: MGX

Price (delayed)

$1.345

Market cap

$50.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.3

Enterprise value

$60.12M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 19
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 32

We are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set ...

Highlights
The debt has declined by 12% year-on-year and by 3.6% since the previous quarter
MGX's quick ratio is down by 11% since the previous quarter but it is up by 10% year-on-year
The net income has declined by 10% year-on-year but it rose by 2.3% since the previous quarter
The revenue has dropped by 51% year-on-year and by 11% since the previous quarter
The company's gross profit has shrunk by 51% YoY and by 11% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.metagenomi.co
Peers: ILMN NTLA CRSP EDIT

Key stats

What are the main financial stats of MGX

MGX stock price

How has the Metagenomi stock price performed over time
Intraday
1.13%
1 week
-3.93%
1 month
-4.61%
1 year
-20.88%
YTD
-16.98%
QTD
0.37%

Financial performance

How have Metagenomi's revenue and profit performed over time
Revenue
$22.33M
Gross profit
$22.33M
Operating income
-$92.78M
Net income
-$85.89M
Gross margin
100%
Net margin
-384.6%
The net margin has dropped by 123% year-on-year and by 10% since the previous quarter
Metagenomi's operating margin has shrunk by 115% YoY and by 9% QoQ
The revenue has dropped by 51% year-on-year and by 11% since the previous quarter
The company's gross profit has shrunk by 51% YoY and by 11% QoQ

Price vs fundamentals

How does MGX's price correlate with its fundamentals

Growth

What is Metagenomi's growth rate over time

Valuation

What is Metagenomi stock price valuation
P/E
N/A
P/B
0.37
P/S
2.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.69
Metagenomi's EPS has decreased by 9% YoY but it has increased by 2.5% from the previous quarter
The equity has declined by 35% year-on-year and by 13% since the previous quarter
The P/B is 10% lower than the last 4 quarters average of 0.4
The revenue has dropped by 51% year-on-year and by 11% since the previous quarter
MGX's price to sales (P/S) is 2.6% lower than its last 4 quarters average of 2.3

Efficiency

How efficient is Metagenomi business performance
Metagenomi's ROS has plunged by 109% YoY and by 10% from the previous quarter
MGX's ROA has shrunk by 61% YoY and by 8% QoQ
Metagenomi's ROE has plunged by 60% YoY and by 9% from the previous quarter
The ROIC has contracted by 48% YoY and by 8% from the previous quarter

Dividends

What is MGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MGX.

Financial health

How did Metagenomi financials performed over time
The total assets has contracted by 34% YoY and by 11% from the previous quarter
Metagenomi's total liabilities has decreased by 31% YoY and by 5% QoQ
The debt is 72% smaller than the equity
The equity has declined by 35% year-on-year and by 13% since the previous quarter
The company's debt to equity rose by 33% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.